In a previous study, we investigated the therapeutic potential of the tumor vascular-disrupting agent ASA404 and its downstream mediator TNFα against endocrine tumors in xenograft models for neuroendocrine tumors of the gastroenteropancreatic system (BON) and adrenocortical carcinoma (NCI-H295R). Here, TNF is linked to neoplasm.